Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by AQR Capital Management LLC

AQR Capital Management LLC increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 31.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 480,186 shares of the company's stock after buying an additional 114,436 shares during the quarter. AQR Capital Management LLC owned about 1.55% of Medpace worth $159,532,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Invesco Ltd. lifted its stake in shares of Medpace by 91.8% in the 4th quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock valued at $360,387,000 after purchasing an additional 519,186 shares during the last quarter. Proficio Capital Partners LLC lifted its holdings in shares of Medpace by 34,497.4% in the 4th quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company's stock worth $80,575,000 after acquiring an additional 241,827 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Medpace in the 4th quarter valued at approximately $78,144,000. Norges Bank purchased a new position in shares of Medpace during the fourth quarter worth $69,859,000. Finally, GW&K Investment Management LLC grew its stake in shares of Medpace by 93.9% in the fourth quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock valued at $91,516,000 after buying an additional 133,379 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Medpace

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the transaction, the director now directly owns 2,998 shares in the company, valued at $904,856.36. This trade represents a 36.35 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 20.30% of the company's stock.

Medpace Trading Up 0.9 %

Shares of NASDAQ MEDP traded up $2.86 during trading hours on Friday, reaching $305.11. The stock had a trading volume of 313,502 shares, compared to its average volume of 342,545. The firm has a 50-day moving average of $309.90 and a 200-day moving average of $330.24. The firm has a market cap of $8.77 billion, a price-to-earnings ratio of 24.16, a PEG ratio of 3.81 and a beta of 1.46. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The business had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. During the same period last year, the firm posted $3.20 earnings per share. On average, equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on MEDP shares. Leerink Partners assumed coverage on Medpace in a report on Monday, March 24th. They set a "market perform" rating and a $330.00 target price for the company. Robert W. Baird reduced their target price on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. TD Cowen cut Medpace from a "buy" rating to a "hold" rating and reduced their price objective for the company from $370.00 to $328.00 in a research note on Monday, April 14th. Truist Financial cut their target price on shares of Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research note on Wednesday, April 23rd. Finally, Mizuho lowered their price target on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a report on Wednesday, April 9th. Eleven analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Medpace presently has a consensus rating of "Hold" and an average target price of $349.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.